Genital Warts
Risk of developing genital wart recurrence after 3 months of 5% imiquimod cream use is low
Published in TB and Outbreaks Week, February 21st, 2006
According to a recently published study from France, "One of the main issues raised by the management of external genital warts is their potential risk of recurrence. However, nearly all studies assessing recurrences have been conducted with a 3-month follow-up.
"Since the latency of the human papillomavirus is long, such 3 month follow-up might be too short to detect the true recurrence rate. We, therefore, conducted a study evaluating patients with external genital warts, treated with an immune response modifier, 558 imiquimod cream, and followed up to 6...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Drug Resistance
Treatment of multidrug resistant TB led to fluoroquinolone resistance in Taiwan - Food Safety
Multiple-restaurant Shigella flexneri serotype 2a infection outbreak traced to tomatoes - Nosocomial Infections
Serratia marcescens bacteriuria outbreaks occurred in neurosurgical ICU - Nosocomial Infections
Infection control measures failed to control carbapenem-resistant P. aeruginosa spread - Nosocomial Infections
Simultaneous S. marcescens and K. pneumoniae outbreak occurred in a neonatal ICU - Allergy & Immunology
TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal MTB resistance - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
